Farmacoterapia antibiótica da pleurisia, empiema pleural e infecções de diversas origens: análise ABC e VED

Introduction: Antibiotic resistance remains one of the greatest challenges in global health, which necessitates a systemic approach to the rational use of antimicrobial medicines, in particular in patients with infections of various genesis, pleurisy, pleural empyema, tuberculosis and chronic infections. In Latin American countries, in particular in Colombia, the problem of uncontrolled antibiotic use is combined with socio-economic factors that affect access to effective pharmacotherapy, especially in patients with pleurisy, pleural empyema, tuberculosis and chronic infections. Objective: To conduct an analysis of antimicrobial medicines registered in Colombia using ABC and VED analysis, to identify priority active substances for further planning of procurement, consumption control strategies, and prescription in the treatment of pleurisy, pleural empyema, tuberculosis and chronic infections. Methodology: The study was based on the analysis of 20 antibacterial drugs registered in Colombia, using international databases, price catalogs, and WHO guidelines. An ABC analysis was performed by cost level, ranking by criticality criterion (VED), and the share of each drug in total costs was calculated. Additionally, literature sources on antimicrobial resistance. Results: The highest share in costs (category A) was made by Ceftriaxone, Amoxicillin/clavulanic acid, and Azithromycin. Within category B, Ciprofloxacin, Doxycycline, and Cefalexin were identified. Category C drugs had a small share of costs, but a high frequency of use. The relationship between price indicators and prevalence of use indicates the need to optimize procurement policies. Discussion: The data obtained emphasize the need to implement antimicrobial stewardship strategies and national monitoring. Conclusions: The results of the study have practical value for health policy, antimicrobial control and the formation of national protocols for the treatment of pleurisy, pleural empyema, tuberculosis and chronic infections. ABC/VED analysis allows to identify critical points in the costs of antibiotics, outlines the prospects for the development of individualized pharmacotherapy in the context of increasing antibiotic resistance.